Abstract
Purpose:
A guidelines for the management of retinal vein occlusion is presented. This is necessary because at this moment several therapeutic alternatives have been developed although their role is not yet sufficiently defined.
Methods:
Review of the literature for evidence published up to date. Relevant literature was identified and the level of evidence graded. Evidence was then assessed for consistency, applicability and clinical impact. The information was contrasted with those guides published in other countries.
Results:
Taking into account the different options of treatment that are currently used, several modes of action are suggested. The role of the various complementary examinations are discussed and it is recommended that criteria for the treatment are based on clinical, angiographic, and tomographic findings.
Conclusions:
Although there is no overall consensus, these guidelines promote a good standard of clinical practise and provide an update of the management of retinal vein occlusion.
Copyright © 2010. Published by Elsevier Espana.
Publication types
-
English Abstract
-
Practice Guideline
MeSH terms
-
Adrenal Cortex Hormones / therapeutic use
-
Aged
-
Aged, 80 and over
-
Algorithms
-
Angiogenesis Inhibitors / therapeutic use
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Humanized
-
Bevacizumab
-
Cardiovascular Diseases / complications
-
Diabetic Retinopathy / diagnosis
-
Diabetic Retinopathy / therapy
-
Evidence-Based Medicine
-
Fluorescein Angiography
-
Glaucoma, Open-Angle / complications
-
Hematologic Agents / therapeutic use
-
Humans
-
Laser Coagulation
-
Light Coagulation
-
Macular Edema / complications
-
Macular Edema / surgery
-
Macular Edema / therapy
-
Middle Aged
-
Retinal Vein Occlusion / diagnosis
-
Retinal Vein Occlusion / drug therapy
-
Retinal Vein Occlusion / etiology
-
Retinal Vein Occlusion / physiopathology
-
Retinal Vein Occlusion / surgery
-
Retinal Vein Occlusion / therapy*
-
Risk Factors
-
Thrombophilia / complications
-
Tomography, Optical Coherence
Substances
-
Adrenal Cortex Hormones
-
Angiogenesis Inhibitors
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Hematologic Agents
-
Bevacizumab